Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H13N.ClH |
Molecular Weight | 195.689 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN(CC#C)CC1=CC=CC=C1
InChI
InChIKey=BCXCABRDBBWWGY-UHFFFAOYSA-N
InChI=1S/C11H13N.ClH/c1-3-9-12(2)10-11-7-5-4-6-8-11;/h1,4-8H,9-10H2,2H3;1H
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2039 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9564606 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Eutonyl Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
75 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/490428/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PARGYLINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
272 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/490428/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PARGYLINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/490428/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PARGYLINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/8114614/ Page: 7.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/8114614/ Page: 7.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/8114614/ Page: 7.0 |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/11306107/ Page: 10.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/11306107/ Page: 10.0 |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Testosterone-attenuated stereotype and hyperactivity induced by beta-phenylethylamine in pargyline-pretreated rats. | 1978 Aug |
|
The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, l-deprenyl and pargyline. | 1982 Nov 15 |
|
Pargyline-induced mania in primary affective disorder: case report. | 1983 Jan |
|
Chronic but not acute treatment with antidepressants enhances the electroconvulsive seizure response in rats. | 1985 Oct |
|
Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat. | 1987 Sep |
|
The involvement of noradrenaline, 5-hydroxytryptamine and acetylcholine in imipramine-induced seizures in mice. | 1993 Oct 15 |
|
The MAO-B inhibitor deprenyl, but not the MAO-A inhibitor clorgyline, potentiates the neurotoxicity of p-chloroamphetamine. | 1994 Jul 11 |
|
GABAergic and dopaminergic systems may be involved in seizures induced by pyrimethamine in mice. | 1994 Oct |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3208065
Curator's Comment: The two molecular forms of monoamine oxidase (MAO), MAO-A and MAO-B, were determined quantitatively in discrete regions of the human brain at autopsy, and in cerebral microvessels, choroid plexus and liver samples from the same subjects. MAO was assessed by specific[3H] pargyline binding, which is stoichiometric and irreversible, and by measuring the rate of oxidation of several MAO substrates. Basal ganglia structures (caudate, putamen, globus pallidus and substantia nigra) and hippocampus had about twice the levels of MAO that were present in the cerebral cortex and cerebellum. Cerebral microvessels, which constitute the blood-brain barrier, had minimal MAO, while the choroid plexus, which constitutes the blood-cerebrospinal fluid barrier, and the liver had higher MAO levels than any brain region. The vast majority of MAO (80-95%) in these tissues was of the B type, except in microvessels, where total MAO activity was low. Specific [3H]pargyline binding correlated well with the oxidation rates for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and benzylamine in all tissues. Both specific [3H]pargyline binding and the rate of oxidation of MAO substrates increased with age.
Unknown
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C667
Created by
admin on Fri Dec 15 16:11:58 GMT 2023 , Edited by admin on Fri Dec 15 16:11:58 GMT 2023
|
||
|
NCI_THESAURUS |
C270
Created by
admin on Fri Dec 15 16:11:58 GMT 2023 , Edited by admin on Fri Dec 15 16:11:58 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID1044647
Created by
admin on Fri Dec 15 16:11:58 GMT 2023 , Edited by admin on Fri Dec 15 16:11:58 GMT 2023
|
PRIMARY | |||
|
206-175-1
Created by
admin on Fri Dec 15 16:11:58 GMT 2023 , Edited by admin on Fri Dec 15 16:11:58 GMT 2023
|
PRIMARY | |||
|
m8412
Created by
admin on Fri Dec 15 16:11:58 GMT 2023 , Edited by admin on Fri Dec 15 16:11:58 GMT 2023
|
PRIMARY | Merck Index | ||
|
82069
Created by
admin on Fri Dec 15 16:11:58 GMT 2023 , Edited by admin on Fri Dec 15 16:11:58 GMT 2023
|
PRIMARY | RxNorm | ||
|
DBSALT000304
Created by
admin on Fri Dec 15 16:11:58 GMT 2023 , Edited by admin on Fri Dec 15 16:11:58 GMT 2023
|
PRIMARY | |||
|
100000085538
Created by
admin on Fri Dec 15 16:11:58 GMT 2023 , Edited by admin on Fri Dec 15 16:11:58 GMT 2023
|
PRIMARY | |||
|
CHEMBL673
Created by
admin on Fri Dec 15 16:11:58 GMT 2023 , Edited by admin on Fri Dec 15 16:11:58 GMT 2023
|
PRIMARY | |||
|
9373
Created by
admin on Fri Dec 15 16:11:58 GMT 2023 , Edited by admin on Fri Dec 15 16:11:58 GMT 2023
|
PRIMARY | |||
|
SUB03653MIG
Created by
admin on Fri Dec 15 16:11:58 GMT 2023 , Edited by admin on Fri Dec 15 16:11:58 GMT 2023
|
PRIMARY | |||
|
43798
Created by
admin on Fri Dec 15 16:11:58 GMT 2023 , Edited by admin on Fri Dec 15 16:11:58 GMT 2023
|
PRIMARY | |||
|
C66323
Created by
admin on Fri Dec 15 16:11:58 GMT 2023 , Edited by admin on Fri Dec 15 16:11:58 GMT 2023
|
PRIMARY | |||
|
W70V6I2OMY
Created by
admin on Fri Dec 15 16:11:58 GMT 2023 , Edited by admin on Fri Dec 15 16:11:58 GMT 2023
|
PRIMARY | |||
|
306-07-0
Created by
admin on Fri Dec 15 16:11:58 GMT 2023 , Edited by admin on Fri Dec 15 16:11:58 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD